Sartar Therapeutics revolutionizes sarcoma therapy. There is an urgent clinical need to find efficacious sarcoma therapies. Sartar
Therapeutics is a preclinical stage biotech company that will meet the need by developing precision medicine products to treat rare cancers. The first product candidate SAR001 is based on Sartar’s repurposed, proprietary reformulated anagrelide. SAR001 is a controlled-release anagrelide product that targets PDE3A protein that is highly expressed in sarcomas such as gastrointestinal stromal tumor, liposarcoma and other soft tissue sarcomas.

  • Founding year: 
  • 2016
  • Development phase:
  • Pre clinical stage
  • Funding stage:
  • A round completed in Q4/2020
  • Website: 
  • Contact person info: 
  • katja.ivanitskiy(at)sartartherapeutics.com
  • Team members:
  • 2
  • Article:
  • Read an article about Sartar Therapeutics.